Health Ingredients

COVID-19 Info: We would like to inform our customers and partners that we are making every effort to ensure the continuity of our services during this time. We applied contingency plans to our production facilities, and — to date — our production is running under strict safety measures to protect the health of our staff. We will keep our customers informed as the situation evolves.

Latest news

Dec
21,
2020

Press Release: Lallemand purchases Biotec BetaGlucans AS

Dec 21, 2020

 

Lallemand purchases Biotec BetaGlucans AS from ArticZymes Technologies ASA.

December 21, 2020

 

Lallemand Inc’s subsidiary, Danstar Ferment AG has signed an agreement to purchase Biotec BetaGlucans AS (BBG), a wholly owned subsidiary of the ArticZymes Technologies ASA (AZT) company, effective December 31, 2020.

AZT is a publicly listed company located in Tromsø, Norway. BBG is specialized in the development, production and sales of high purity beta-glucan products, from yeast cell walls, sold as immune ingredients for human health supplements and in aquaculture.  BBG’s high purity yeast beta-glucan technology and patented soluble beta-glucan (SBG) offer potential for several other applications and markets.

The acquisition includes a specialized pharma and food grade certified production plant located in Tromsø, Northern Norway with an experienced team.

Under the terms of the agreement, Lallemand will acquire all of the BBG assets and associated intellectual property including the M-Gard®, SBG®, M-Glucan® and Woulgan® branded product portfolios, and will assume manufacturing responsibilities for beta-glucans in the Nordøya, Tromsø manufacturing facility.

The BBG business is an excellent strategic fit for Lallemand, a global leader in the development, production and marketing of yeast, bacteria and specialty ingredients.

 

President and CEO of Lallemand Inc., Antoine Chagnon commented:

“Our acquisition of the Biotec BetaGlucans business will broaden our beta-glucans product portfolio as well as our access to leading technologies within yeast-based ingredients. We look forward to offering our customers in both human and animal nutrition sectors innovative products from Biotec BetaGlucans. We are delighted to have secured the pharma certified Tromsø plant, our first production facility in Norway.”

 

AZT CEO, Jethro Holter said:

“We are delighted to divest BBG to Lallemand who is ideally suited to take over this business. AZT will subsequently become a pure enzyme company with all efforts focused towards expanding it enzymes portfolio through organic and inorganic growth initiatives.”

-ENDS-

 

For more information, please contact:

Karen Dhanraj, Technical Marketing Manager, Lallemand Bio-Ingredients

Email: kdhanraj@lallemand.com

Website: www.bio-lallemand.com

 

About Lallemand Inc.

Lallemand is a family owned business, headquartered in Canada, whose focus is on the development, production and marketing of yeasts, bacteria and enzymes solutions across the baking, food ingredients, human and animal nutrition and health, crop protection/nutrition, oenology, brewing, alcohol and biofuel sectors. Lallemand is present in more than 50 countries, operates more than 45 production plants and has approximately 4,500 employees.

For more information, please visit the website: www.Lallemand.com

 

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing and commercialization of novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec] ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.

ArcticZymes Technologies’ unique IP and capabilities are protected via a large portfolio of patents.

For more information, please visit the website: www.arcticzymes.com